SYDNEY — CSL Limited (ASX:CSL) has staged a remarkable recovery from its 52-week trough, clawing back approximately A$16 billion in market capitalisation. The stock closed Friday at A$123.32, up 1.12% on the day and posting a modest 0.35% gain over the week. However, that weekly performance lagged behind two key competitors in the plasma-derived therapies space.
The rebound represents a 37% surge from the A$90 low, but CSL still trades 55% below its 52-week high, with a market capitalisation of A$59.06 billion. Volume on Friday reached 1.62 million shares, roughly 14% below the average daily turnover of 1.88 million.
Underperformance Against Peers
While CSL outperformed the broader S&P/ASX 200 index by 0.46 percentage points over the week, it trailed Grifols SA (BME:GRF) by 1.60 points and Takeda Pharmaceutical Co (TYO:4502) by 1.91 points. Grifols, a pure-play plasma medicines company, rose 1.95% for the week after launching two Phase 3 immunoglobulin trials on July 16. Takeda, which also counts plasma-derived treatments as a major segment, gained 2.26%.
Friday’s session was more favourable for CSL, which outperformed the ASX 200 by 1.62 percentage points as the index slipped 0.50%.
Catalysts and Headwinds Ahead
CSL is set to release its full-year financial results on August 18. The company’s May update projected approximately US$15.2 billion in revenue for FY26, with NPATA expected to reach about US$3.1 billion at constant currency. An initial impairment estimate of US$5 billion in non-cash, pre-tax charges, covering FY26 and FY27, remains pending audit and board clearance.
Interim CEO Gordon Naylor acknowledged that growth initiatives are delivering, but noted that “the financial benefits will take longer than previously anticipated to materialise.” The company has also flagged a US$150 million revenue headwind from slower HEMGENIX growth, increased iron competition, and geopolitical tensions.
External Risks
Geopolitical risks have escalated, with Brent crude closing at $88.10 on Friday, up about 16% over the week amid rising US-Iran tensions. CSL has cited this dispute as a factor contributing to its revenue headwind.
On the upside, a faster normalisation of US immunoglobulin inventory could boost reported sales. Conversely, further declines in China albumin pricing, larger-than-expected impairments, or fresh regional disruptions could derail the recovery.
No company events are scheduled this week. All eyes are on the August 18 results, when CSL will provide an updated impairment estimate.
